|N-(2-(7-甲氧基萘-1-基)乙基)乙酰胺|CsnPharm

CAS No.: 138112-76-2

Agomelatine/阿戈美拉汀 Catalog No. CSN16711

Synonyms: S-20098;Valdoxan;Thymanax

Agomelatine is a melatonin structurely similar 5-HT2C receptor antagonist as well as a potent melatonin receptor agonist, used to treat major depressive disorder.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Agomelatine dose-dependently inhibits the firing of cells in the SCN (the endogeneous master clock) in Syrian hamsters (ED50 = 0.91 mg/kg, i.p.)^[3]. In CSDS (chronic social defeat stress) mice treated 3 weeks with 50 mg/kg/d agomelatine, the anxious-like phenotype was not reversed, but the treatment successfully prevented the cognitive impairments and hippocampal gene expression modifications^[4].
细胞研究

Cell Data

Cell Lines	Concentration	Assay Type	Time	Activity Description	Data Sources
CHO cells	-	Function assay	120 mins	Displacement of [125I]iodomelatonin form human MT1 receptor expressed in CHO cells after 120 mins, Ki=0.1 nM	22301214
CHO-Galpha16 cells	-	Function assay	20 mins	Binding affinity to rat MT1 receptor expressed in CHO-Galpha16 cells assessed as Ca2+ mobilization after 20 mins by FLIPR assay, EC50=2.1 nM	21237644
HEK 293	-	Function assay	-	Binding affinity for human Melatonin receptor type 1A stably transfected in human embryonic kidney cells (HEK 293) using 2-[125I]iodomelatonin as radioligand, Ki=6e-05 μM	12646022

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02400346	Major Depression Disorder	Phase 3	Completed	-	-
NCT02374567	Dementia Depr... more >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Collapse <<	Phase 3	Terminated	-	Germany ... more >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Collapse <<
NCT02400346	-	-	Completed	-	-

更多
参考文献

[1] Dagytė G, Crescente I, et al. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav Brain Res. 2011 Mar 17;218(1):121-8.
[2] Zajecka J, Schatzberg A, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr;30(2):135-44.
[3] Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014 Aug;171(15):3604-19. doi: 10.1111/bph.12720. PMID: 24724693; PMCID: PMC4128060.
[4] Martin V, Allaïli N, Euvrard M, Marday T, Riffaud A, Franc B, Mocaër E, Gabriel C, Fossati P, Lehericy S, Lanfumey L. Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Sci Rep. 2017 Apr 4;8:45907. doi: 10.1038/srep45907. PMID: 28374847; PMCID: PMC5379201.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 4.1101 mL
- 20.5507 mL
- 41.1014 mL
- 5 mM
- 0.8220 mL
- 4.1101 mL
- 8.2203 mL
- 10 mM
- 0.4110 mL
- 2.0551 mL
- 4.1101 mL

技术信息

CAS号

138112-76-2

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C15H17NO2

运输

蓝冰

分子量

243.30

别名

S-20098;Valdoxan;Thymanax;Melitor;AGO-178;N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide;阿戈美拉汀

溶解度

DMSO	46.0 mg/mL (189.1 mM)
Water	Insoluble
Ethanol	47.0 mg/mL (193.2 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02400346	Major Depression Disorder	Phase 3	Completed	-	-
NCT02374567	Dementia Depr... more >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Collapse <<	Phase 3	Terminated	-	Germany ... more >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Collapse <<
NCT02400346	-	-	Completed	-	-
NCT03193112	-	-	Completed	-	Turkey ... more >> Kahramanmaras Sutcuimam University Ophthalmology Department Kahramanmaraş, Turkey, 46050 Collapse <<
NCT00451490	Depressive Disorder, Major	Not Applicable	Withdrawn(This study not get t... more >>he approval by the drug company) Collapse <<	December 2007	Taiwan ... more >> National Taiwan University Hospital Taipei, Taiwan, 100 Collapse <<
NCT00411099	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01110889	Major Depressive Disorder	Phase 3	Completed	-	-
NCT00467402	Major Depressive Disorder	Phase 3	Completed	-	-
NCT00411242	Major Depressive Disorder (MDD... more >>) Collapse <<	Phase 3	Completed	-	-
NCT01110902	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01156415	Major Depressive Disorder	Phase 3	Terminated	-	-
NCT01488071	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01459250	Renal Impairment	Phase 1	Completed	-	United States, Florida ... more >> Novartis Investigative Site Miami, Florida, United States, 33136 Novartis Investigative Site Orlando, Florida, United States, 32809-3017 United States, Minnesota Novartis Investigative Site Minneapolis, Minnesota, United States, 55404 United States, Tennessee Novartis Investigative Site Knoxville, Tennessee, United States, 37920 Collapse <<
NCT01488071	-	-	Completed	-	-
NCT00463242	Major Depressive Disorder	Phase 3	Completed	-	-
NCT01531309	Hepatic Impairment	Phase 1 Phase 2	Completed	-	United States, Florida ... more >> Orlando Clinical Research Center Orlando, Florida, United States, 32809 Collapse <<
NCT01108393	Obsessive Compulsive Disorder	Phase 2	Completed	-	Israel ... more >> Department of Psychiatry Chaim Sheba Medical Center Tel Hashomer, Israel Collapse <<
NCT01822418	Schizophrenia ... more >> Schizoaffective Disorder Delusional Disorder Collapse <<	Phase 4	Completed	-	Germany ... more >> Central Institute of Mental Health Mannheim, Baden-Württemberg, Germany, 68159 Collapse <<
NCT01731899	-	-	Completed	-	Spain ... more >> Instituto de Neurociencias Granada, Spain, 18012 Collapse <<
NCT01483053	Major Depressive Disorder (MDD... more >>) Collapse <<	Phase 4	Unknown	February 2015	Australia, Victoria ... more >> Monash Medical Centre - Monash Health Not yet recruiting Clayton, Victoria, Australia, 3168 Principal Investigator: David Barton Sub-Investigator: Arup Dhar Sub-Investigator: Sarah Tremethick Sub-Investigator: Jennifer Grigo Sub-Investigator: Krishna Vaddadi Alfred and Baker Medical Unit - Alfred Hospital Not yet recruiting Melbourne, Victoria, Australia, 3004 Principal Investigator: Gavin Lambert Sub-Investigator: Arup Dhar Sub-Investigator: Sarah Tremethick Sub-Investigator: Jennifer Grigo Sub-Investigator: Markus Schlaich Sub-Investigator: Elisabeth Lambert Sub-Investigator: Murray Esler Sub-Investigator: Geoff Head Sub-Investigator: Nina Eikelis Sub-Investigator: Carolina Ika Sari Sub-Investigator: Petra Marusic Sub-Investigator: Toni Rice Sub-Investigator: Mariee Grima Sub-Investigator: Donna Vizi Sub-Investigator: Louise Hammond Sub-Investigator: David Barton Sub-Investigator: Dagmara Hering Baker IDI Heart & Diabetes Institute Not yet recruiting Melbourne, Victoria, Australia, 3004 Principal Investigator: Gavin Lambert Sub-Investigator: Arup Dhar Sub-Investigator: Sarah Tremethick Sub-Investigator: Jennifer Grigo Sub-Investigator: Markus Schlaich Sub-Investigator: Elisabeth Lambert Sub-Investigator: Murray Esler Sub-Investigator: Geoff Head Sub-Investigator: Nina Eikelis Sub-Investigator: Carolina Ika Sari Sub-Investigator: Petra Marusic Sub-Investigator: Toni Rice Sub-Investigator: Mariee Grima Sub-Investigator: Donna Vizi Sub-Investigator: Louise Hammond Sub-Investigator: David Barton Sub-Investigator: Dagmara Hering Collapse <<

Agomelatine/阿戈美拉汀 Catalog No. CSN16711

靶点选择性

请登录您的专属账户

确认信息